| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 7507730 | Drug and Alcohol Dependence | 2013 | 7 Pages |
Abstract
Dronabinol's ability to dose-dependently suppress cannabis withdrawal may be therapeutically beneficial to individuals trying to stop cannabis use. The absence of gross cognitive impairment or side effects in this study supports safety of doses up to 120Â mg/day. Continued evaluation of dronabinol in targeted clinical studies of cannabis treatment, using an expanded range of doses, is warranted.
Related Topics
Life Sciences
Neuroscience
Behavioral Neuroscience
Authors
Ryan Vandrey, Maxine L. Stitzer, Miriam Z. Mintzer, Marilyn A. Huestis, Jeannie A. Murray, Dayong Lee,